As the Democratic Republic of the Congo grapples with the fastest-growing Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) is spotlighting its hemorrhagic fever vaccine expertise and candidate portfolio, signaling readiness to contribute to the global response. The outbreak, caused by the Bundibugyo virus (BDBV), has already surpassed 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO), and is on a trajectory that could exceed the toll of the 2014-2016 West Africa epidemic. Currently, no approved vaccine specifically targets Bundibugyo virus.
GeoVax, a biotechnology company developing vaccines and immunotherapies, has extensive experience in leveraging its Modified Vaccinia Ankara (MVA) platform to develop vaccines against high-consequence hemorrhagic fever viruses. Its portfolio includes candidates targeting Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, which have demonstrated encouraging protective efficacy in non-human primate lethal-challenge studies.
David Dodd, Chairman and Chief Executive Officer of GeoVax, emphasized the urgency: "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs. We are prepared to engage with WHO, Africa CDC, national public health authorities and other appropriate organizations to determine whether our vaccine candidates, technology or scientific expertise could contribute to the response. Where appropriate, we are also willing to make relevant vaccine materials available for evaluation against Bundibugyo virus."
GeoVax's lead infectious disease priority remains GEO-MVA, its MVA-based vaccine for mpox and smallpox. The company is preparing a pivotal clinical development program based on an immunobridging accelerated regulatory pathway, with portions planned in African regions confronting significant infectious disease challenges, including areas affected by the current Ebola outbreak. As part of these preparations, GeoVax is already engaging with healthcare and research organizations in the region, which provides a natural avenue to explore contributions to the Ebola response.
Dodd added: "Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak. Given our experience, we believe it is appropriate to ask how we might help. Any such effort would be pursued collaboratively while maintaining our operational and capital focus on GEO-MVA."
Beyond GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates that have shown protective efficacy in animal models. The company is open to collaborations, licensing arrangements, public-private partnerships, and other strategic structures that could provide resources for further evaluation and development of these assets without diverting primary resources from GEO-MVA.
GeoVax believes its combination of MVA platform expertise, hemorrhagic fever vaccine candidates, and work on scalable MVA manufacturing provides a foundation for potential collaborations addressing Ebola and other emerging infectious disease threats. The company's broader strategy includes advancing GEO-MVA through a pivotal immunobridging clinical program, while also pursuing innovations in continuous cell-line manufacturing, single-dose regimens, and microarray patch delivery technology to address historical limitations of MVA vaccines.
For more information about GeoVax and its programs, visit GeoVax's website.
